UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 81-3676773 (State or other jur ...

Call Start: 08:00 January 1, 0000 8:42 AM ET Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q2 2022 Earnings Conference Call August 12, 2022 08:00 ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Don Marvin - Chief Financial Officer & Chief Operating Officer Conference Call Participants Jeff Jones - Oppenheimer Kristen Kluska - Cantor Fitzgerald Nathan Weinstein - Aegis Capit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 81-3676773 (State or other jurisdic ...

Pioneering Innovative Treatments for Fibrotic Diseases Corporate Overview | Nasdaq: CMMB | Non-Confidential | June 2022 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achie ...

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & CEO David Weiner - Interim CMO Don Marvin - CFO, COO & EVP Adi Mor - Co-Founder & Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Nathan Weinstein - Aegis Capital Operator Greetings and welcome to the Chemomab First Quarter 2022 E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 81-3676773 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-38807 (Commission file number) | --- | --- | --- | |-------------------------------------------------------------------------------------------------------- ...

Chemomab Therapeutics Ltd (NASDAQ:CMMB) Q4 2021 Earnings Conference Call March 9, 2022 10:00 AM ET Company Participants Dale Pfost – Chief Executive Officer Donald Marvin – Chief Operating Officer and Executive Vice President David Weiner – Chemomab Interim Chief Medical Officer Barbara Lindheim – Consulting Vice President Investor & Public Relations Conference Call Participants Kristen Kluska – Cantor Fitzgerald Nathan Weinstein – Aegis Capital Operator Greetings. Welcome to Chemomab Fourth Quarter and Ful ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 81-3676773 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38807 Chemomab Therapeutics Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 81-3676773 (State or other jurisdic ...